Reports Q1 revenue $1.764M, consensus $2.29M. “To date, eight patients have reached functional cure following imdusiran combination therapy. Of particular note, two of those functional cure patients did not receive any interferon during the trial,” said Lindsay Androski, President and CEO of Arbutus. “There are more than 250 million people suffering from cHBV globally. This type of functional cure data, in patients who successfully discontinued all cHBV treatments including NUCs, is an exciting milestone for Arbutus, clinicians, and patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABUS:
- Arbutus Biopharma Unveils Promising HBV Treatment Data
- Arbutus Biopharma presents data from two HBV assets
- Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025
- Arbutus Biopharma Faces Executive Changes Amid Legal Battle
- Arbutus Biopharma’s Strategic Restructuring and Legal Prospects Justify Buy Rating